G protein-coupled receptor

D2 receptor

Dopamine D2 receptor

The human D2 receptor was cloned from the pituitary. A single gene gives rise to two splice variants, a longer and a shorter form, which differ by 29 amino acids in the third intracellular loop. These amino acids are encoded by a separate exon, and mRNA for both forms is found in the pituitary and brain of both rats and humans.1,2,3 It belongs to the D2-class dopamine receptors together with the D3 and D4 receptors. These couple to Gi/o proteins and so inhibit adenylyl cyclase, and they also activate potassium channels. The gene for the D2 receptor has six introns, whereas the genes of the D1 and D5 receptors have none.4,5 The two splice forms have different roles. The short form, D2S, is mostly presynaptic and takes part in the autoreceptor functions, while the long form, D2L, is predominantly postsynaptic.4

The highest levels of D2 receptors are found in the striatum, the nucleus accumbens and the olfactory tubercle. They are also expressed at significant levels in the substantia nigra, the ventral tegmental area, the hypothalamus, cortical areas, the septum, the amygdala and the hippocampus.4 In postmortem human brain, autoradiography with the agonist CV 205-502 and the antagonist spiroperidol gave very similar patterns. The highest densities were in the caudate nucleus, the putamen, the nucleus accumbens and the olfactory tubercle, followed by the substantia nigra, where the receptors were mainly in the pars compacta. Densities were lower in the lateral globus pallidus and in the CA1 and CA3 fields of the hippocampus, low in the medial globus pallidus, the dentate gyrus and the amygdala, and almost negligible in most of the neocortex, the cerebellum and the brainstem.6

Antipsychotic drugs block the binding of dopamine and haloperidol in the striatum, and how strongly they block it follows their clinical potency against schizophrenia. This held for the antipsychotics tested.7,8 Essentially all clinically effective antipsychotics can block D2 receptors, which indicates that the receptor plays a critical role in the psychotic reactions of schizophrenia and bipolar disorder.4 PET scans of patients showed that classic antipsychotics at usual doses occupied 70 to 89 percent of D2 receptors, and that patients with acute movement side effects had higher occupancies. Clozapine occupied fewer, 38 to 63 percent.9 In a double-blind study, 22 patients with a first episode of schizophrenia received 1.0 or 2.5 mg of haloperidol a day, and the occupancy of D2 receptors, measured with raclopride and PET after two weeks, ranged from 38 to 87 percent. The likelihood of a clinical response, of raised prolactin and of extrapyramidal side effects rose significantly once the occupancy exceeded 65, 72 and 78 percent.10

A review proposes that atypical antipsychotics differ from the older ones because they dissociate faster from the D2 receptor. According to the authors, this allows an antipsychotic effect without motor side effects, prolactin elevation or secondary negative symptoms. They argue that freedom from motor side effects results from low D2 occupancy and not from high 5-HT2 occupancy, and they set their view against the hypotheses that need several receptors.11 Quetiapine at 300 to 600 mg a day showed an occupancy of less than 20 percent 12 hours after a dose, but occupancies in the 60 percent range after 2 hours, which fits a fast decline of the occupancy.11

Dopamine plays a pivotal role in the regulation of prolactin, which is made by the lactotroph cells of the anterior pituitary. The raised prolactin under antipsychotics correlates mostly with their affinity for D2 receptors at these cells. The highest rates of hyperprolactinaemia are reported for amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favourable profile. All second-generation antipsychotics can raise prolactin, especially at the beginning of treatment.12

Mice without D2 receptors are akinetic and slow and move less on their own, which resembles Parkinson's disease.13

Sources (13)
  1. Dal Toso et al. 1989Dal Toso R, Sommer B, Ewert M, et al. (1989) The dopamine D2 receptor: two molecular forms generated by alternative splicing EMBO J
  2. Grandy et al. 1989Grandy DK, Marchionni MA, Makam H, et al. (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor Proc Natl Acad Sci U S A
  3. Giros et al. 1989Giros B, Sokoloff P, Martres MP, et al. (1989) Alternative splicing directs the expression of two D2 dopamine receptor isoforms Nature
  4. Beaulieu et al. 2011Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors Pharmacol Rev
  5. Missale et al. 1998Missale C, Nash SR, Robinson SW, et al. (1998) Dopamine receptors: from structure to function Physiol Rev
  6. Camps et al. 1989Camps M, Cortés R, Gueye B, et al. (1989) Dopamine receptors in human brain: autoradiographic distribution of D2 sites Neuroscience
  7. Seeman et al. 1975Seeman P, Chau-Wong M, Tedesco J, et al. (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays Proc Natl Acad Sci U S A
  8. Seeman et al. 1976Seeman P, Lee T, Chau-Wong M, et al. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors Nature
  9. Farde et al. 1992Farde L, Nordström AL, Wiesel FA, et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch Gen Psychiatry
  10. Kapur et al. 2000Kapur S, Zipursky R, Jones C, et al. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am J Psychiatry
  11. Kapur et al. 2001Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis Am J Psychiatry
  12. Peuskens et al. 2014Peuskens J, Pani L, Detraux J, et al. (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review CNS Drugs
  13. Baik et al. 1995Baik JH, Picetti R, Saiardi A, et al. (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors Nature

Binding affinity (Kᵢ)

15 substances, 17 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

14 measurements
  • LSDAgonistother reports differ39 nMJanowsky et al. 2014 · 2 reports
    Assay
    HEK cells expressing recombinant human D2; [3H]YM-09151-2 competition binding
    Shown value from
    Janowsky et al. 2014, Table 5
    Range
    39–200 nM in 2 reports
    Error
    ± 1.8 SEM

    This is the best-supported value. Other reports differ. 4 reports in all, 25–200 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Jain et al. 2025200 nMTable S4
    Janowsky et al. 201439 nMTable 5
  • ETH-LAD160 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • AL-LAD270 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • Mescaline300 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • 2C-C2100 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 400 SD
  • 2C-B2200 nMRickli et al. 2015 · 2 reports
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Range
    2200–3371 nM in 2 reports
    Error
    ± 300 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Ray 20103371 nMTable S2 (AllKiData)
    Rickli et al. 20152200 nMTable 2
  • 2C-P2300 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 700 SD
  • 2C-I2700 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 580 SD
  • DMT3000 nMRickli et al. 2016
    Assay
    HEK293 membranes expressing human D2; [3H]spiperone displacement
    Shown value from
    Rickli et al. 2016, Table 2
    Error
    ± 400 SD
  • 2C-E3200 nMRickli et al. 2015 · 2 reports
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Range
    3200–3339 nM in 2 reports
    Error
    ± 1000 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Ray 20103339 nMTable S2 (AllKiData)
    Rickli et al. 20153200 nMTable 2
  • 5-MeO-DMT3562 nMRay 2010
    Assay
    PDSP receptorome (compiled; species not stated per entry, predominantly human clones)
    Shown value from
    Ray 2010, Table S2 (AllKiData)
  • Psilocin3700 nMRickli et al. 2016 · 2 reports
    Assay
    HEK293 membranes expressing human D2; [3H]spiperone displacement
    Shown value from
    Rickli et al. 2016, Table 2
    Range
    2300–3700 nM in 2 reports
    Error
    ± 600 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Rickli et al. 20163700 nMTable 2
    Jain et al. 20252300 nMTable S4
  • 4-HO-MET4000 nMRickli et al. 2016
    Assay
    HEK293 membranes expressing human D2; [3H]spiperone displacement
    Shown value from
    Rickli et al. 2016, Table 2
    Error
    ± 200 SD
  • 2C-D7100 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 1700 SD

Rat

1 measurement
  • ETH-LADsource not traced4.4 nMHoffman et al. 1985
    Assay
    rat striatal homogenate; [3H]spiperone competition
    Shown value from
    Hoffman et al. 1985, Part III introduction

Unspecified

2 measurements
  • LSDAgonistdepends on assay155 nMPaulke et al. 2013 · 2 reports
    Assay
    long D2 receptor binding assay; pKi converted to Ki
    Shown value from
    Paulke et al. 2013, Table 2
    Range
    25–155 nM in 2 reports

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 25–155 nM.

  • LSAdepends on assay891 nMPaulke et al. 2013 · 2 reports
    Assay
    long D2 receptor binding assay; pKi converted to Ki
    Shown value from
    Paulke et al. 2013, Table 2
    Range
    145–891 nM in 2 reports

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 145–891 nM.

Functional potency (EC₅₀)

6 substances, 11 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

5 measurements
  • DizocilpineAgonist8.0 nMSeeman et al. 2005
    Assay
    cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
    Shown value from
    Seeman et al. 2005, Results, Figure 2
  • LSDAgonist40 nMSeeman et al. 2005
    Assay
    cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
    Shown value from
    Seeman et al. 2005, Results (data not shown in the figure)
    Emax
    80.0%
  • Salvinorin AAgonist48 nMSeeman et al. 2009
    Assay
    cloned human D2Long receptors, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 4.0 SEM
    Emax
    62.0 ± 4.0%
  • KetamineAgonistunresolved110 nMSeeman et al. 2005 · 2 reports
    Assay
    cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
    Shown value from
    Seeman et al. 2005, Results, Figure 2
    Range
    110–900 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 110–900 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Kapur et al. 2002900 nMResults, Figure 4
    Seeman et al. 2005110 nMResults, Figure 2
  • PCPAgonistunresolved144 nMSeeman et al. 2009 · 3 reports
    Assay
    postmortem human striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Range
    90–4000 nM in 3 reports
    Error
    ± 71 SEM
    Emax
    49.0 ± 4.7%

    Reported values disagree and no value is established. 3 reports in all, 90–4000 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Seeman et al. 2009144 nMTable I
    Kapur et al. 20024000 nMResults, Figure 4
    Seeman et al. 200590 nMResults, Figure 2

Rat

6 measurements
  • PCPAgonist70 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 30 SEM
    Emax
    46.0 ± 4.0%
  • Salvinorin AAgonist89 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 11 SEM
    Emax
    44.0 ± 2.0%
  • 3-HO-PCPAgonist103 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 9.0 SEM
    Emax
    36.0 ± 5.0%
  • LSDAgonist105 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 36 SEM
    Emax
    36.0 ± 3.0%
  • DizocilpineAgonist710 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 190 SEM
    Emax
    29.0 ± 6.0%
  • KetamineAgonist1033 nMSeeman et al. 2009
    Assay
    rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
    Shown value from
    Seeman et al. 2009, Table I
    Error
    ± 329 SEM
    Emax
    27.0 ± 3.0%

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.